Background-The
C ontrast-induced nephropathy (CIN) is a possible complication of coronary diagnostic and interventional procedures. Its development is associated with increased short-term and long-term morbidity and mortality, prolonged hospitalization, and long-term renal impairment. [1] [2] [3] [4] [5] [6] [7] [8] [9] Several risk factors for CIN have been identified. 5, 7, 10, 11 Increasing evidence exists that primary percutaneous coronary intervention (PCI) obtains rapid restoration of coronary artery patency and increases threatened myocardium salvage, thus preserving ventricular function and improving survival of patients with acute myocardial infarction (AMI). 12 However, patients treated with primary PCI represent a population at higher risk for CIN than those undergoing elective PCI, especially in patients presenting with hemodynamic instability and poor ejection fraction. 4 Different studies have recently demonstrated that renal insufficiency and AMI represent a high-risk combination. 4, 13 Moreover, other clinical observations have shown that renal dysfunction is an independent risk factor for death in AMI patients. 4, 14, 15 
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The Mehran CIN-Risk score (MRS) was developed and initially validated for prediction of CIN after nonurgent PCI in patients undergoing angioplasty. 11 This score includes 8 clinical and procedural variables: age Ͼ75 years, hypotension, congestive heart failure, intra-aortic balloon pump, serum creatinine, diabetes, anemia, and volume of contrast. The distribution of the risk score has been divided into 4 class of risk (7.5%, 14.0%, 26.1%, and 57.3% of probability to develop CIN).
The purpose of this study was to assess the predictive power of the MRS in patients undergoing primary angioplasty for ST-elevation-myocardial infarction (STEMI) in predicting CIN and major adverse cardiovascular and cerebrovascular events (MACCE) in both short-and long-term follow-up.
Methods

Study Population
From 2002 to 2008, we enrolled all consecutive patients admitted to our coronary care unit for STEMI who were treated with primary PCI. According to our institute protocol, patients were included if they presented within 12 hours from symptom onset (characteristic chest pain lasting for at least 30 minutes, not responsive to nitrates, with ECG ST-segment elevation of at least 0.2 mV in 2 or more contiguous leads, or development of new left bundle-branch block). Patients in chronic peritoneal or hemodialysis treatment and patients with cardiogenic shock were excluded. The study was approved by the ethic committee of our institution, and informed consent was obtained from all patients.
Study Protocol
Hydration was not routinely performed by the ambulance, helicopter, or emergency room medical staff before arrival in the catheterization laboratory. After contrast exposure, all patients underwent the following hydration protocol: physiological (0.9%) saline was given intravenously at a rate of 1 mL/kg per hour for 12 hours in patients with left ventricular dysfunction (ejection fraction Յ30%) or overt heart failure; hydration rate was reduced to 0.5 mL/kg per hour.
A combination prophylaxis with N-acetylcysteine and NaHCO 3 was administered from the beginning of the procedure, according to the ejection fraction values and Killip class.
The use of ␤-adrenergic-blocking agents, angiotensin-converting enzyme inhibitors, diuretics, or the indication to intra-aortic balloon pump or inotropic drugs support was left to the discretion of the interventional and coronary care unit cardiologists, according to our institute's clinical protocols and international guidelines. 16, 17 An echocardiographic evaluation was performed in all patients before the procedure to assess wall motion abnormalities and ejection fraction. Serum creatinine concentration was measured at the time of admission (just before primary PCI), every day for the following 3 days, and at discharge from the coronary care unit. Estimated glomerular filtration rate was calculated by applying the Levy modified MDRD formula to the creatinine. 18 A dedicated nephrologist consultant was available for the clinical care of patients with impaired renal function during hospitalization.
Primary PCI
Primary PCI was performed by a 24-hour on-call interventional team, according to standard clinical practice. All patients received a loading dose of 300 mg of clopidogrel, in combination with 100 mg of acetylsalicylic acid. After sheath insertion, a heparin bolus at a dose of 70 U/kg, followed by an additional bolus during the procedure to maintain activated clotting time Ͼ300 seconds if deemed necessary, and an intravenous bolus and an infusion of platelet glycoprotein IIb/IIIa receptor inhibitors (abciximab) were administered. Contrast type and dose and supportive pharmacological therapies were left to the discretion of the interventional cardiologist.
Follow-Up
All patients were followed in the outpatient clinic of the Cardiology Unit at Modena University Hospital, with a clinical examination at 1, 6, and 12 months and yearly thereafter. In addition, a telephone interview to the patients or his or her general practitioner was done for the patients who failed to present during follow-up in the outpatient clinic. Events recorded were cardiac and noncardiac death, occurrence of new Q and non-Q myocardial infarction, major stroke, need of target lesion revascularization, coronary artery bypass graft surgery (CABG) performed after the emergency procedure, recurrent hospitalization for angina, or congestive heart failure.
Definitions
CIN was defined as a 0.5 mg/dL (44 mmol/L) increase in serum creatinine or 25% increase compared with baseline values within 48 hours of the procedure. 19 Chronic renal insufficiency was defined as estimated glomerular filtration rate Ͻ60 mL/min per 1.73 m 2 , based on the MDRD equation. 20 Anemia was defined using World Health Organization criteria such as a baseline hemoglobin value Ͻ13 g/dL for men and Ͻ12 g/dL for women. 21 Major bleeding was defined according as an intracranial hemorrhage or Ն5 g/dL decrease in the hemoglobin concentration or a Ն15% absolute decrease in the hematocrit. 22 Hypotension was defined as systolic blood pressure Ͻ80 mm Hg for at least 1 hour requiring inotropic support with medications or intra-aortic balloon pump within 24 hours of the procedure. Congestive heart failure was defined as New York Heart Association functional classification III/IV and/or history of pulmonary edema. Diabetes was defined using the criteria of the expert committee on the diagnosis and classification of diabetes mellitus, such as fasting plasma glucose Ն7.0 mmol/L (126 mg/dL) or 2-hour plasma glucose Ն11.1 mmol/L (200 mg/dL). 23 A lifetime history of Ͼ100 cigarettes was considered a positive smoking history. 24 The primary end point of the study was the rate of MACCE defined as the composite of death, stroke, nonfatal AMI, and repeated revascularization of target vessel by PCI or CABG operation during hospital stay or during follow-up. Table 1 shows the criteria for the MRS calculation. 11 IABP indicates intra-aortic balloon pump; CHF, congestive heart failure; and eGFR, estimated glomerular filtration rate (mL/min per 1.73 m 2 ).
Statistical Analysis
Based on the MRS stratification, the population was divided into 4 groups (low, medium, high, and very high risk of CIN). Continuous data are reported as meanϮSD unless otherwise specified. Categorical data are presented as absolute values and percentages. Comparison of continuous variables was performed by the use of ANOVA test. The Fisher exact 2 test was used for comparison of categorical variables.
Survival and cumulative incidence of events were represented using Kaplan-Meier curves. The significance of the curves was tested using the log-rank test. For MACCE criteria, in the case of multiple events, the first episode was taken as the standard.
During follow-up, variables predictive of events were calculated through univariable and multivariable analysis, by logistic regression, and Cox regression and presented with, respectively, odds ratios (OR) or hazard ratios (HR) and 95% confidence intervals (CI).
Covariates were selected on a prior knowledge of factors assessed in the emergency department that are known predictors of mortality. Covariates were kept in the models, regardless of significance, and the stratified Cox model was adjusted for demographics (sex, weight), risk factors (history of smoking, active smoking, hypertension, familiar history of cardiovascular disease), and presenting and periprocedural characteristics (Killip class, anterior MI, door-toballoon time, multivessel coronary disease, postprocedural TIMI flow, and development of CIN).
The accuracy of the risk score was tested using the receiver operating characteristic analysis and evaluating the area under curve (AUC or C-statistics). The Harrel C-statistic was used for the long-term follow-up events.
The accuracy of the MRS was compared with the accuracy of the Marenzi CIN risk score for STEMI. 4 The Marenzi CIN risk score is composed of 5 variables: age Ն75 years, anterior AMI, time to reperfusion Ն6 hours, contrast agent volume Ն300 mL, and use of intra-aortic balloon pump A value of 1 was assigned when a factor was present and 0 when it was absent. For each patient, the score was calculated as the sum of the number of variables (range, 0 to 5).
All tests were 2-tailed, and probability was considered to be statistically significant at Ͻ0.05. All analyses were performed using STATA/SE software, version 10.0 for Windows.
Results
Patient Characteristics
Of a total of 1046 STEMI patients, 155 were excluded (94 with cardiogenic shock, 18 in chronic peritoneal or hemodialysis treatment, and 43 for inability to calculate MRS, eg, for hemolysis of initial blood collection in the emergency department). Hence, a total of 891 patients (522 men, 369 women; mean age, 64Ϯ13 years) were included in this study. Follow-up was completed in 891 (100%) patients at 1 year. The median follow-up period was 24.7Ϯ19.2 months, with up to 85.5 months of follow-up. Table 2 shows the baseline clinical and procedural characteristics of the CIN risk groups at the time of primary PCI. With the increasing severity of risk of CIN (RC) scores, the percentage of smokers, men, patients with familiar history of cardiovascular disease, and preprocedural left ventricular ejection fraction progressively decreased, whereas the percentage of patients with hypertension increased. A positive trend with hypotension, intra-aortic balloon pump, age, anemia, diabetes, and contrast media volume and a negative trend with estimated glomerular filtration rate were seen with increasing risk group because these variables define the risk score calculation.
Short-Term Clinical Events and Predictive Value of MRS
Overall, 126 (14.14%) patients had CIN (Table 3) . When creatinine clearance was estimated, 169 (18.97%) of 891 patients had an impaired renal function (Ͻ60 mL/min). Of these, 24 (14.20%) had CIN. Similarly, of the 722 (81.03%) patients with a baseline creatinine clearance value Ն60 mL/min, 102 (14.13%) had CIN after primary PCI (Pϭ0.980).
During the 48 hours after the procedure, the following events were observed: 11 (1.23%) deaths: none in the low-risk group, 4 (1.84%) in the medium-risk group, 4 (4.82%) in the high-risk group, and 3 (10.34%) in the very high-risk group (PϽ0.001), respectively. Of those who died, none had CIN.
At univariable analysis, the OR for CIN was 3.82 (95% CI, 1.71 to 8.57; Pϭ0.001) in the very high-risk group, as compared with the lowest group, 1.73 (95% CI, 0.95 to 3.17; Pϭ0.073) in the high-risk group and 1.26 (95% CI, 0.79 to 1.98; Pϭ0.323) in the medium-risk group.
As shown in Table 4 , at the multivariable analysis, the OR for CIN was 2.84 (95% CI, 1.16 to 6.92; Pϭ0.021) in the very high RC group as compared with the lowest group, but there were no significant differences between the low-risk group versus the medium-risk and versus the high-risk group (Pϭ0.073 and Pϭ0.220, respectively).
Long-Term Clinical Events and Predictive Value of MRS
During follow-up, a total of 105 (11.78%) patients died, 70 (7.86%) had recurrent MI, 200 (22.45%) had repeat PTCA, 29 (3.25%) had CABG, 82 (9.20%) had rehospitalization, 19 (2.13%) had major stroke, and 365 (40.97%) had a MACCE. Figure depicts the Kaplan-Meier estimates of the cumulative probability of death, rehospitalization, and MACCE as stratified by the 4 classes of risk. The significance of all the curves was confirmed using the log-rank test (PϽ0.001). Table 3 shows the events stratified by MRS. Mortality, reinfarction, hospitalization for angina or congestive heart failure, and composite end point were significantly increased across strata (respectively, PϽ0.001, Pϭ0.003, and PϽ0.001), with the greatest estimated number of events occurring in the highest MRS group. 
Discrimination of the Risk Scores
The AUC estimates from the MRS and the Marenzi risk score crude models shows similar accuracy in CIN prediction, with an AUC of 0.57 (95% CI, 0.52 to 0.62) and 0.57 (95% CI, 0.51 to 0.62), respectively. Comparing the accuracy of MRS versus the Marenzi risk score in death prediction, the C-statistics obtained were 0.74 (95% CI, 0.59 to 0.79) and 0.60 (95% CI, 0.55 to 0.65), respectively; in MACCE, predictions were 0.61 (95% CI, 0.55 to 0.67) versus 0.57 (95% CI, 0.54 to 0.60); in rehospitalization, predictions were 0.66 (95% CI, 0.60 to 0.72) versus 0.57 (95% CI, 0.50 to 0.64), and in reinfarction, predictions were 0.63 (95% CI, 0.57 to 0.70) versus 0.56 (95% CI, 0.49 to 0.63). 
Discussion
The findings of the present study can be summarized as follows. First, patients with the higher score of the MRS are associated with a 10-fold higher risk of death compared with the lower ones. Second, the MRS is a good predictor of the risk to develop MACCE during short-and long-term followup. Third, the MRS can be applied in the STEMI population for a better stratification of the risk of CIN development.
Several STEMI risk scores (TIMI Risk Score, GRACE, CADILLAC, PAMI, and Zwolle) [25] [26] [27] [28] [29] have been developed to facilitate the decision-making process and predict adverse clinical outcomes in patients treated with fibrinolytics or PCI. In a similar way, different scores have been developed to predict the risk of CIN in elective o primary PCI. 4, 30 Nevertheless, scores validated in both contexts have not been evaluated before. The MRS seems to answer to the question of an all-around score for CIN, mortality, MACCE, and rehospitalization prediction in STEMI. The score efficacy in both contexts is related to the role of renal function as a major determinant of cardiovascular outcome in a variety of settings, including hypertension, chronic heart failure, acute coronary syndromes, AMI, elective PCI, and surgical coronary revascularization. 16, 31 Furthermore, CIN risk factors, such as anemia and diabetes, are harmful for coronary heart disease. 16, 31 Regardless of the underlying mechanism, an increase in creatinine concentration during the acute phase of STEMI may represent a surrogate for more severe and extensive atherosclerosis and circulatory instability. 32 Marenzi et al 4 identified a strict relationship between CIN development and impaired renal function (estimated glomerular filtration rate Ͻ60 mL/min) before the procedure. In our study population, it was not possible to confirm such relationship, with no significant differences between groups stratified for estimated glomerular filtration rate 4, 33 These data may be related to the exclusion of patients with cardiogenic shock from our study population. In addition, the close collaboration with the local nephrologist in our institution may have reduced the risk of CIN development as the result of a prompt activation of the hydration protocol. At multivariable analysis, the predictive power of MRS was confirmed by the increase in the HR with the increasing value of risk score (1.10, 1.34, and 2.84, respectively), although a significant value was reached only for the very high-risk group.
A hypothesis explaining the lower CIN predictive power of the score among mortality rates was relative to the clinical importance of CIN development in STEMI setting. The number of deaths during the 48 hours after the procedure progressively increased with the increasing of the class of risk (0.00%, 1.84%, 4.82%, and 10.34%), but none of the patients had CIN. Considering the crucial link between cardiac and renal dysfunction and extending the observation of the negative impact on survival deriving from the association between cardiac and renal disease in patients with AMI undergoing primary PCI, 4 it is possible to hypothesize that these patients died before having instrumental manifestations of CIN. Moreover, it is not possible to exclude that with the increased risk of CIN and, accordingly, with the increase of congestive heart failure rate, a dilutional effect on serum creatinine values may determine a shift of patients from a borderline value to lower classes of risk.
Although all our patients effectively underwent contrast media exposure and 14.11% had acute renal failure up to 48 hours after it, we cannot exclude the possibility that other factors, such as hemodynamic instability, might have contributed, at least in part, to renal impairment and influenced the clinical outcome of our patients. Indeed, in addition to contrast agent volume, other factors reflecting cardiocirculatory impairment, such as anterior AMI, longer time to reperfusion, and need for intra-aortic balloon pump, were independently related to the development of renal dysfunction. This confirms that kidney hypoperfusion, resulting in ischemic renal injury, might play a major role. However, despite the fact that no firm conclusions can be drawn at this stage, our data suggest that there is a potential strategy for further reduction of mortality after primary PCI. This could probably be obtained on the one hand through newer therapies aimed at preventing acute renal dysfunction, such as hemofiltration, and on the other by shortening time to reperfusion and minimizing contrast volume.
Study Limitations
The present study has several limitations. First, the MRS was not previously tested for outcome prediction other than CIN. Thus, the scope of the other analyses is exploratory and hypothesis-generating only. Second, it included a small population, admitted to a single center. Our findings should be confirmed and the application of the risk score validated in a larger multicenter trial. Third, the definition of CIN is based on the absolute or relative increase in creatinine level compared with baseline value, after a patient has been exposed to a contrast agent, although CIN may describe a risk not entirely attributable to contrast exposure. 
Conclusion
The Mehran CIN Risk Score can be also applied in a STEMI population and is able to predict CIN development and to discriminate between low-, medium-, high, and very high-risk patient subgroups for consequent poor clinical outcomes during both short-and long-term follow-up.
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